Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Treatment of non-Hodgkin lymphoma

The results from treatment have improved, especially for aggressive lymphomas. This is due to better diagnostics, more intense induction treatment with combination chemotherapy as well as the introduction of monoclonal antibodies. The more patients that reach complete remission as early as possible, the more long-term survivors there will be. Treatment of the most aggressive lymphomas (lymphoblastic and Burkitt's lymphoma) has changed the most in recent years. These lymphomas are treated using leukemia protocols and 50-70% are long-term survivors. Today about 50-60% of patients with other aggressive non-Hodgkins lymphomas are cured. The more slow-growing, indolent non-Hodgkin lymphomas also have new treatment principles which may extend total survival for this patient group.

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2018